Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 24Carcinoma, Renal Cell 16Stomach Neoplasms 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Hepatocellular 6Kidney Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Mesothelioma 4Adenocarcinoma Of Esophagus 4Skin Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Anus Neoplasms 3Various Advanced Cancer 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mesothelioma, Malignant 2Liver Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma 2Anal Canal Carcinoma 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Lenalidomide 3capivasertib 2Bortezomib 2tivozanib 1Zoledronic Acid 1Vitamin D 1Temozolomide 1Radiotherapy 1Nivolumab 1Gemcitabine 1Fulvestrant 1Etoposide 1Dexamethasone 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1Calcium 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Disease Progression × Nivolumab × Clear all
NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡